| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9959928 | Journal of the American College of Cardiology | 2005 | 8 Pages |
Abstract
These data suggest that bosentan, an oral endothelin ETA/ETBreceptor antagonist, with or without concomitant prostanoid therapy, is safe and efficacious for the treatment of PAH in children.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Erika Berman MD, D. Dunbar MD, Allison MS, PA, Aimee RN, MS, CPNP, Lori R. RN, Delphine MD, Steven H. MD, Adele PhD, Ngoc BS, Robyn J. MD,